Glimzab MP 1mg/500mg/15mg Tablet SR
Marketer
Neucure Lifesciences Private Limited
Salt Composition
Glimepiride (1mg) + Metformin (500mg) + Pioglitazone (15mg)
Overview Glimzab MP 1mg/500mg/15mg Tablet SR
Glimzab MP 1mg/500mg/15mg extended-release tablets offer a multi-component approach to managing blood glucose. This medication, used alongside diet and exercise, enhances glycemic control in adult patients with type 2 diabetes. It facilitates efficient insulin use, consequently reducing blood sugar. Adhere strictly to your physician's prescribed dosage and regimen for Glimzab MP. Ingestion with food mitigates potential stomach discomfort. If a dose is missed, administer it promptly unless the next dose is imminent; in that case, omit the missed dose and resume the usual schedule. Never double the dose. Excessive intake can result in hypoglycemia (low blood sugar). Concurrent use with other antidiabetic medications, alcohol, or skipped meals elevates the risk of hypoglycemia. Regular blood glucose monitoring is crucial. Commonly reported adverse effects include nausea, diarrhea, abdominal pain, headache, bone fractures, and respiratory infections. Prior to commencing treatment, disclose any existing kidney, liver, or heart conditions to your doctor. Pregnant or lactating individuals must consult their physician before initiating therapy. Kidney function assessment will be conducted before treatment begins. Limit alcohol consumption while on this medication to minimize the likelihood of adverse events.
Uses of Glimzab MP 1mg/500mg/15mg Tablet SR
Managing type 2 diabetes
Major Benefits of Glimzab MP 1mg/500mg/15mg Tablet SR:
Follow your doctor's instructions precisely regarding the dosage and treatment length for this medication. Ingest the Glimzab MP 1mg/500mg/15mg Tablet SR whole; avoid crushing, chewing, or breaking it. Administer this medication with a meal.
Common Side effects of Glimzab MP 1mg/500mg/15mg Tablet SR:
- Hypoglycemia (low blood glucose level)
- Headache
- Nausea
- Diarrhea
- Dizziness
- Vomiting
- Anemia (low number of red blood cells)
- Weakness
- Sinus infection
How to use Glimzab MP 1mg/500mg/15mg Tablet SR:
Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment duration. Ingest the entire tablet; avoid chewing, crushing, or fracturing it. The Glimzab MP 1mg/500mg/15mg Extended-Release tablet should be administered with a meal.
How Glimzab MP 1mg/500mg/15mg Tablet SR works:
Glimzab MP 1mg/500mg/15mg Extended-Release tablets combine glimepiride, metformin, and pioglitazone—three distinct antidiabetic agents. This triple therapy offers enhanced blood glucose management when monotherapy or dual drug regimens prove insufficient. Glimepiride, a sulfonylurea, stimulates pancreatic insulin secretion to reduce blood sugar. Metformin, a biguanide, acts by decreasing hepatic glucose production, slowing intestinal glucose absorption, and improving insulin responsiveness. Pioglitazone, a thiazolidinedione, further augments insulin sensitivity.
SAFETY ADVICE
AlcoholUNSAFE
Consuming alcohol while taking Glimzab MP 1mg/500mg/15mg SR tablets is not advisable due to safety concerns.
PregnancyCONSULT YOUR DOCTOR
The use of Glimzab MP 1mg/500mg/15mg SR tablets during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the potential advantages against any possible hazards before prescribing this medication. Physician consultation is advised.
Breast feedingCONSULT YOUR DOCTOR
The extended-release Glimzab MP 1mg/500mg/15mg tablet likely poses a risk during lactation. Available human data indicates potential transfer to breast milk, with the possibility of infant harm.
DrivingCAUTION
Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if these conditions arise.
KidneyCAUTION
Patients with kidney impairment should use Glimzab MP 1mg/500mg/15mg SR tablets cautiously, potentially requiring dosage modification. Consult a physician for guidance. Glimzab MP 1mg/500mg/15mg SR tablets are contraindicated in individuals with severe kidney disease. Routine monitoring of kidney function is recommended during treatment.
LiverCAUTION
Exercise caution when administering Glimzab MP 1mg/500mg/15mg SR tablets to individuals with hepatic impairment; dosage modification may be necessary. Consult a physician for guidance. Glimzab MP 1mg/500mg/15mg SR tablets are contraindicated in patients exhibiting severe liver dysfunction.
What if you forget to take Glimzab MP 1mg/500mg/15mg Tablet SR :
Should you forget to take a Glimzab MP 1mg/500mg/15mg Tablet SR, administer it immediately upon recollection. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Glimzab MP 1mg/500mg/15mg Tablet SR
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Diabetes Management |


